BIOHAVEN PHARMACTL HLDG CO L's ticker is BHVN and the CUSIP is G11196105. A total of 309 filers reported holding BIOHAVEN PHARMACTL HLDG CO L in Q1 2022. The put-call ratio across all filers is 0.75 and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $37,747,000 | -18.1% | 318,354 | -4.5% | 0.19% | -4.5% |
| Q4 2021 | $46,115,000 | -1.0% | 333,516 | -0.6% | 0.20% | -3.8% |
| Q3 2021 | $46,599,000 | +23.2% | 335,462 | -13.9% | 0.21% | +29.6% |
| Q2 2021 | $37,834,000 | +37.2% | 389,722 | -3.5% | 0.16% | +32.8% |
| Q1 2021 | $27,568,000 | -42.4% | 403,882 | -27.7% | 0.12% | -54.8% |
| Q4 2020 | $47,893,000 | +16.5% | 558,786 | -14.2% | 0.27% | +27.4% |
| Q3 2020 | $41,127,000 | -8.0% | 651,165 | +1.0% | 0.21% | -16.5% |
| Q2 2020 | $44,696,000 | +77.1% | 644,779 | -13.1% | 0.25% | +61.8% |
| Q1 2020 | $25,240,000 | -37.9% | 741,719 | -0.6% | 0.16% | -19.5% |
| Q4 2019 | $40,642,000 | -1.0% | 746,549 | -24.2% | 0.20% | -8.0% |
| Q3 2019 | $41,066,000 | – | 984,335 | – | 0.21% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RP Management, LLC | 1,111,111 | $107,867,000 | 52.60% |
| Knoll Capital Management, LLC | 856,844 | $83,182,000 | 43.44% |
| ORACLE INVESTMENT MANAGEMENT INC | 2,082,555 | $202,174,000 | 27.86% |
| ARS Investment Partners, LLC | 558,286 | $54,198,000 | 5.52% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 176,400 | $17,113,000 | 4.52% |
| KINGDON CAPITAL MANAGEMENT, L.L.C. | 401,006 | $38,930,000 | 4.51% |
| Eventide Asset Management | 1,990,797 | $193,267,000 | 2.60% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 56,626 | $5,497,000 | 2.45% |
| Avidity Partners Management LP | 882,500 | $85,673,000 | 2.32% |
| Nicholas Investment Partners, LP | 363,708 | $35,309,000 | 2.22% |